AGENDA

In the “Green Rush” cash grab, it is important to protect early adopters from larger, poaching companies.

The verticals of this young industry still face regulatory challenges. We want a simplified legal environment for integrating businesses from seed to sale. The technology piece of this business needs updating, software like METRC needs to improve so we can track the plant throughout the seed to sale process.

This is critical for protecting both patients and the labs who are already doing their due diligence from corner cutters and “half-steppers”. Regulatory strength here would be a hallmark of a serious, maturing industry.

And not just an unlicensed person growing in their garage…we need legal protection against large land grabs and unregulated price gougers who side skirting testing.

We need to even the playing field for our growers who are doing things the right way while protecting both the land and our patients.

Cash-only transactions do not signal serious, mature industry. They are frowned upon in regulatory environments.

Researchers lead to some of our greatest opportunities, but must be protected from the need to churn out profits in the same way as scientists in other fields.

OMMA should be independent from controlling stakeholders.

Limited patient access was never a permanent solution. Instead of relying on State.

In the world of online ordering and app delivery service, our industry suffers from undue regulation here.